Gemcitabine and targeted therapy in metastatic breast cancer

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

1996 • 754 citations

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

1997 • 721 citations

Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

1991 • 480 citations

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

1998 • 386 citations

Advanced breast cancer: a phase II trial with gemcitabine.

1995 • 340 citations

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.

1993 • 333 citations

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1995 • 324 citations

Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial

2001 • 308 citations

Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer

2001 • 252 citations

Cisplatin as first-line therapy for metastatic breast cancer.

1988 • 220 citations

Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.

1994 • 191 citations

Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.

1994 • 164 citations

Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer

1999 • 132 citations

Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules

1990 • 111 citations

Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer Patients

2000 • 105 citations

Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial

1999 • 93 citations

Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer

2000 • 80 citations

Phase II study of gemcltablne in patients with metastatic breast cancer

1997 • 74 citations

Docetaxel and Gemcitabine in Anthracycline-Resistant Advanced Breast Cancer: A Hellenic Cooperative Oncology Group Phase II Study

2000 • 63 citations

Phase II Trial of the Use of Paclitaxel and Gemcitabine as a Salvage Treatment in Metastatic Breast Cancer

2001 • 45 citations

Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony‐stimulating factor

1999 • 41 citations

Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.

2000 • 35 citations

Capecitabine in colorectal cancer.

2001 • 35 citations

Update on the management of advanced breast cancer.

1999 • 33 citations

Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.

1995 • 30 citations

Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.

2001 • 23 citations

Biweekly Gemcitabine, Doxorubicin, and Paclitaxel as First-Line Treatment in Metastatic Breast Cancer

2001 • 16 citations